Levine, A. J. & Oren, M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749–758 (2009).
Shaw, P. H. The role of p53 in cell cycle regulation. Pathol. Res. Pract. 192, 669–675 (1996).
Vousden, K. H. & Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275–283 (2007).
Vousden, K. H. & Ryan, K. M. p53 and metabolism. Nat. Rev. Cancer 9, 691–700 (2009).
The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008 (2010).
Bertheau, P. et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast 22, S27–S29 (2013).
Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268–1286 (2012).
Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nat. Cell Biol. 15, 2–8 (2013).
Yue, X. et al. Mutant p53 in cancer: accumulation, gain-of-function, and therapy. J. Mol. Biol. 429, 1595–1606 (2017).
Lukashchuk, N. & Vousden, K. H. Ubiquitination and degradation of mutant p53. Mol. Cell Biol. 27, 8284–8295 (2007).
Schulz-Heddergott, R. et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell 34, 298–314 (2018).
Zhang, C. et al. Gain-of-function mutant p53 in cancer progression and therapy. J. Mol. Cell Biol. 12, 674–687 (2020).
Bykov, V. J. N., Eriksson, S. E., Bianchi, J. & Wiman, K. G. Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer 18, 89–102 (2018).
Parrales, A. & Iwakuma, T. Targeting oncogenic mutant p53 for cancer therapy. Front. Oncol. 5, 288 (2015).
Zhang, Y. J. et al. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8. Biomaterials 271, 120720 (2021).
Qian, J. et al. Enhancing chemotherapy of p53‐mutated cancer through ubiquitination‐dependent proteasomal degradation of mutant p53 proteins by engineered ZnFe‐4 nanoparticles. Adv. Funct. Mater. 30, 2001994 (2020).
Kocaturk, N. M. & Gozuacik, D. Crosstalk between mammalian autophagy and the ubiquitin–proteasome system. Front. Cell Dev. Biol. 6, 128 (2018).
Jing, M. et al. Photoresponsive PAMAM-assembled nanocarrier loaded with autophagy inhibitor for synergistic cancer therapy. Small 17, e2102295 (2021).
Lee, C. W. et al. Selective autophagy degrades nuclear pore complexes. Nat. Cell Biol. 22, 159–166 (2020).
Zhang, Y. et al. Harnessing copper–palladium alloy tetrapod nanoparticle-induced pro-survival autophagy for optimized photothermal therapy of drug-resistant cancer. Nat. Commun. 9, 4236 (2018).
Khaminets, A., Behl, C. & Dikic, I. Ubiquitin-dependent and independent signals in selective autophagy. Trends Cell Biol. 26, 6–16 (2016).
Kirkin, V. & Rogov, V. V. A diversity of selective autophagy receptors determines the specificity of the autophagy pathway. Mol. Cell 76, 268–285 (2019).
Shaid, S., Brandts, C. H., Serve, H. & Dikic, I. Ubiquitination and selective autophagy. Cell Death Differ. 20, 21–30 (2013).
Sarraf, S. A. et al. Loss of TAX1BP1-directed autophagy results in protein aggregate accumulation in the brain. Mol. Cell 80, 779–795 (2020).
Jo, C. et al. Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nat. Commun. 5, 3496 (2014).
Pankiv, S. et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282, 24131–24145 (2007).
Guida, E. et al. Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res. 68, 6550–6558 (2008).
Man, N., Chen, Y., Zheng, F., Zhou, W. & Wen, L. P. Induction of genuine autophagy by cationic lipids in mammalian cells. Autophagy 6, 449–454 (2010).
Roberts, R. et al. Autophagy and formation of tubulovesicular autophagosomes provide a barrier against nonviral gene delivery. Autophagy 9, 667–682 (2013).
Li, M. et al. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972–1975 (2003).
Li, M., Luo, J., Brooks, C. L. & Gu, W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277, 50607–50611 (2002).
Maeda, H., Nakamura, H. & Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65, 71–79 (2013).
Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 (2007).
Alexandrova, E. M. et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523, 352–356 (2015).
Ghosh, M. et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell 39, 494–508 (2021).
Baslan, T. et al. Ordered and deterministic cancer genome evolution after p53 loss. Nature 608, 795–802 (2022).
Parrales, A. et al. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat. Cell Biol. 18, 1233–1243 (2016).
Proia, D. A. & Bates, R. C. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res. 74, 1294–1300 (2014).
Padmanabhan, A. et al. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat. Commun. 9, 1270 (2018).
Garufi, A. et al. Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis. 5, e1271 (2014).
Li, Z. et al. Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds. Nature 575, 203–209 (2019).
Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015).
Li, H. J. et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc. Natl Acad. Sci. USA 113, 4164–4169 (2016).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41565-023-01562-5
- ][p
- 003
- 01
- 07
- 08
- 09
- 1
- 10
- 11
- 12
- 13
- 14
- 15%
- 16
- 17
- 19
- 1996
- 20
- 2008
- 2010
- 2011
- 2012
- 2013
- 2014
- 2015
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 35%
- 36
- 39
- 40
- 41
- 43
- 7
- 72
- 75
- 8
- 9
- a
- accumulation
- After
- against
- aggregate
- aggregates
- AL
- Alloy
- an
- analyses
- and
- article
- AS
- atlas
- barrier
- between
- Biomaterials
- Brain
- Breast cancer
- by
- Cancer
- Cancer cells
- cancers
- cell
- Cells
- chemotherapy
- chen
- click
- Clinical
- complex
- Consequences
- control
- controls
- cycle
- Death
- delivery
- dependence
- determines
- Dev
- differ
- directly
- Disease
- distinct
- Diversity
- drug
- Drug Delivery
- e
- E&T
- effect
- efficacy
- efficient
- emerging
- engineered
- enhancing
- Ether (ETH)
- EVER
- evolution
- facilitate
- fate
- First
- For
- formation
- genome
- genuine
- Growing
- Growth
- Harnessing
- Health
- http
- HTTPS
- human
- i
- ii
- Imaging
- immune
- improved
- improvement
- improving
- in
- independent
- induction
- innate
- insights
- integrated
- into
- invasion
- ITS
- Lane
- levels
- LINK
- loss
- lowering
- many
- MOL
- more
- name
- nanotechnology
- Nature
- network
- New
- nuclear
- of
- on
- ONE
- optimized
- origins
- Ovarian Cancer
- pathway
- penetration
- platform
- plato
- Plato Data Intelligence
- PlatoData
- preclinical
- progression
- promise
- promote
- Protein
- Proteins
- provide
- R
- reduces
- reference
- Regulation
- research
- response
- Results
- Role
- Ryan
- s
- Scholar
- SCI
- selective
- serve
- signals
- solid
- specificity
- spring
- Strategy
- survival
- synergistic
- system
- systemic
- T
- Target
- targeting
- The
- Therapeutic
- therapy
- Through
- to
- treatment
- tumor
- tumors
- turnover
- uptake
- use
- Versus
- vivo
- W
- with
- X
- years
- zephyrnet
